ABX 101 - Autobahn Therapeutics
Alternative Names: ABX-101 - Autobahn TherapeuticsLatest Information Update: 29 Aug 2024
At a glance
- Originator Autobahn Therapeutics
- Class Anti-inflammatories; Neuroprotectants; Small molecules
- Mechanism of Action Sphingosine 1 phosphate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurodegenerative disorders; Unspecified
Most Recent Events
- 29 Aug 2024 Autobahn Therapeutics plans a phase I trial in an unspecified disorder (PO) in the first half of 2025 (Autobahn Therapeutics pipeline, August 2024)
- 11 Sep 2023 Autobahn Therapeutics plans IND-enabling studies in Neurodegenerative disorders (PO) in 2024
- 11 Sep 2023 Preclinical trials in Neurodegenerative disorders in USA (PO) prior to September 2023